scholarly journals Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

2002 ◽  
Vol 61 (10) ◽  
pp. 883-888 ◽  
Author(s):  
M J Leandro
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Outcome ◽  
B Lymphocyte ◽  
Lymphocyte Depletion

B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders

2002 ◽  
Vol 30 (4) ◽  
pp. 824-828 ◽  
Author(s):  
J. C. W. Edwards ◽  
M.J. Leandro ◽  
G. Cambridge
Keyword(s):  
Rheumatoid Arthritis ◽  
B Lymphocyte ◽  
Lymphocyte Subsets ◽  
Autoimmune Disorders ◽  
Lymphocyte Depletion ◽  
Rate Limiting Step ◽  
Limiting Step ◽  
Early Evidence ◽  
Wide Range ◽  
Rate Limiting

B-lymphocyte depletion therapy is being explored in a wide range of autoimmune disorders. In many, there is early evidence for efficacy, and immunosuppression has not been a major problem. The mechanism of action is unclear, but appears to be consistent with the lowering of autoantibody levels, where relevant antibodies are quantifiable. An interesting finding is the persistence of clinical improvement for periods of 1 year or more after B-lymphocyte return, which supports the concept that stochastic generation of rare pathogenic B-lymphocyte subsets may be a rate-limiting step in pathogenesis.

scholarly journals Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

2003 ◽  
Vol 48 (8) ◽  
pp. 2146-2154 ◽  
Author(s):  
Geraldine Cambridge ◽  
Maria J. Leandro ◽  
Jonathan C. W. Edwards ◽  
Michael R. Ehrenstein ◽  
Martin Salden ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
B Lymphocyte ◽  
Lymphocyte Depletion

scholarly journals Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs

Rheumatology ◽  
2006 ◽  
Vol 46 (4) ◽  
pp. 626-630 ◽  
Author(s):  
C. Popa ◽  
M. J. Leandro ◽  
G. Cambridge ◽  
J. C. W. Edwards
Keyword(s):  
Rheumatoid Arthritis ◽  
B Lymphocyte ◽  
Lymphocyte Depletion

B lymphocyte depletion therapy with rituximab in rheumatoid arthritis

2004 ◽  
Vol 30 (2) ◽  
pp. 393-403 ◽  
Author(s):  
J.C.W Edwards ◽  
M.J Leandro ◽  
G Cambridge
Keyword(s):  
Rheumatoid Arthritis ◽  
B Lymphocyte ◽  
Lymphocyte Depletion

Long-term B-lymphocyte depletion and remission of granulomatosis with polyangiitis after two courses of rituximab treatment

Rheumatology ◽  
2020 ◽  
Author(s):  
Larissa Valor-Méndez ◽  
Arnd Kleyer ◽  
Jürgen Rech ◽  
Bernhard Manger ◽  
Georg  Schett
Keyword(s):  
Granulomatosis With Polyangiitis ◽  
B Lymphocyte ◽  
Lymphocyte Depletion

FRI0126 POOR ADHERENCE TO METHOTREXATE IS ASSOCIATED WITH PERSISTENT DISEASE ACTIVITY DURING FOLLOW-UP FOR RHEUMATOID ARTHRITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 644.1-645
Author(s):  
J. H. Kang ◽  
S. E. Choi ◽  
H. Xu ◽  
D. J. Park ◽  
S. S. Lee
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Outcome ◽  
Disease Activity ◽  
Reactive Protein ◽  
Rate Score ◽  
Tertiary Center ◽  
Proportion Of Days Covered ◽  
Euroqol 5D ◽  
Control Disease

Objectives:Although methotrexate (MTX) is the cornerstone therapy in patients with rheumatoid arthritis (RA), adherence to MTX in these patients is typically suboptimal. Thus, we investigated the proportion of RA patients who were adherent to MTX and whether non-adherence to MTX affected the clinical outcome in these patients during follow-up.Methods:We enrolled 331 RA patients from a single tertiary center. Data were collected at the time of enrollment and then annually for 4 consecutive years. Adherence was defined by the proportion of days covered at 1 year. Patients were divided into two groups: patients who took more than 80% of MTX and those who did not. Univariate and multivariate analyses were performed to identify the association between drug compliance and clinical outcome.Results:Of the 331 RA patients, 8.7% had taken less than 80% of MTX during the follow-up period. Non-adherent patients had lower EuroQol-5D scores (P=0.013) and higher RAPID3 scores (P=0.004) at baseline than adherent patients. Leflunomide was more commonly prescribed to adherent patients than non-adherent patients (P=0.012). Non-adherent patients had a higher mean Disease Activity Score 28 (DAS28)-erythrocyte sedimentation rate score (P=0.001), higher mean DAS28-C-reactive protein (CRP) score (P=0.001), and higher mean rate of tender and swollen joints (P=0.003 and P=0.002, respectively) than adherent patients. In the multivariate analysis, poor MTX adherence was significantly associated with a higher mean DAS28-CRP score (odds ratio, 0.270; 95% confidence interval, 0.165–0.444; P<0.001).Conclusion:Adherence to MTX can affect disease activity during follow-up in Korean patients with RA. Our results provide a rationale for patient education to maintain good drug adherence in RA patients, to control disease activity.Disclosure of Interests:None declared

scholarly journals Evidence of Intrathyroidal B-Lymphocyte Depletion after rituximab Therapy in a Patient with Graves’ Disease

2007 ◽  
Vol 92 (10) ◽  
pp. 3762-3763 ◽  
Author(s):  
Daniel El Fassi ◽  
Ole Clemmensen ◽  
Claus H. Nielsen ◽  
Rona Z. Silkiss ◽  
Laszlo Hegedüs
Keyword(s):  
B Lymphocyte ◽  
Graves Disease ◽  
Lymphocyte Depletion

Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study

2013 ◽  
Vol 40 (5) ◽  
pp. 579-589 ◽  
Author(s):  
William Stohl ◽  
Joan T. Merrill ◽  
James D. McKay ◽  
Jeffrey R. Lisse ◽  
Z. John Zhong ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Phase Ii ◽  
B Lymphocyte ◽  
Tumor Necrosis Factor Inhibitor ◽  
Open Label ◽  
Double Blind ◽  
Acr20 Response ◽  
Link Type ◽  
American College Of Rheumatology

Objective.To evaluate the efficacy/safety of belimumab in patients with rheumatoid arthritis (RA).Methods.Patients fulfilling American College of Rheumatology (ACR) criteria for RA for ≥ 1 year who had at least moderate disease activity while receiving stable disease-modifying antirheumatic drug (DMARD) therapy and failed ≥ 1 DMARD were randomly assigned to placebo or belimumab 1, 4, or 10 mg/kg, administered intravenously on Days 1, 14, and 28, and then every 4 weeks for 24 weeks (n = 283). This was followed by an optional 24-week extension (n = 237) in which all patients received belimumab. Primary efficacy endpoint was the Week 24 ACR20 response.Results.Week 24 ACR20 responses with placebo and belimumab 1, 4, and 10 mg/kg were 15.9%, 34.7% (p = 0.010), 25.4% (p = 0.168), and 28.2% (p = 0.080), respectively. Patients taking any belimumab dose who continued with belimumab in the open-label extension had an ACR20 response of 41% at 48 weeks. A similar ACR20 response (42%) at 48 weeks was seen in patients taking placebo who switched in the extension to belimumab 10 mg/kg. Greater response rates were observed in patients who at baseline were rheumatoid factor-positive, anticitrullinated protein antibody-positive, or tumor necrosis factor inhibitor-naive, or had elevated C-reactive protein levels, Disease Activity Score 28 > 5.1, or low B lymphocyte stimulator levels (< 0.858 ng/ml). Adverse event rates were similar across treatment groups.Conclusion.In this phase II trial, belimumab demonstrated efficacy and was generally well tolerated in patients with RA who had failed previous therapies. [ClinicalTrials.gov identifier NCT00071812]

scholarly journals Association among B lymphocyte subset and rheumatoid arthritis in a Chinese population

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Haiyan You ◽  
Mengwei Cheng ◽  
Cui Ma ◽  
Wenjuan Zheng ◽  
Yu Jiang ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Healthy Subjects ◽  
B Lymphocyte ◽  
Lymphocyte Subsets ◽  
Characteristic Curve ◽  
Area Under The Curve ◽  
Enzyme Linked Immunosorbent Assay ◽  
Roc Curve Analysis ◽  
Autoantibody Production ◽  
Plasma Cytokines

Abstract Background and aim Autoantibody production are the main risk factors for inflammation of rheumatoid arthritis (RA). This study aimed to investigate differences in B lymphocyte subsets (native B, memory B, and plasmablasts) and several cytokines in RA patients and their correlation with the clinical parameters. Methods In total, 81 RA patients (active RA and inactive RA) and 40 healthy subjects were recruited between September 2018 and October 2020. The distribution of B lymphocyte subsets in peripheral blood samples was measured via flow cytometry and the plasma cytokines were detected by enzyme linked immunosorbent assay. The receiver operating characteristic curve (ROC) was used to evaluate the value of each index for RA diagnosis and activity prediction. Results The percentages of native B and memory B cells in RA patients did not differ significantly from the percentages of those in healthy controls. However, the percentage of plasmablasts in active RA patients was significantly higher compared with healthy subjects and inactive RA patients. The percentage of plasmablasts was significantly related to C reaction protein. ROC curve analysis showed that when the best cutoff value of plasmablasts/B cell was 1.08%, the area under the curve (AUC) for diagnosing RA was 0.831 (95% CI 0.748 ~ 0.915), the specificity was 91.4%, and the sensitivity was 67.5%. The AUC predicted by the combination of plasmablast and anti-CCP for active RA patients was 0.760, which was higher than that of plasmablast and anti-CCP. Conclusion In conclusion, the percentage of plasmablast varies among RA patients in different stages. The percentage of plasmablasts can be used as an early diagnosis marker for RA.

Sign in / Sign up

Export Citation Format

Share Document